Jaguar Health Inc Stock Research

Market Summary

USD4.99+0.04

Delayedas of 25 Jan 2023, 03:52 pm

0.81%

JAGX Stock Price

JAGX RSI Chart

JAGX Valuation

Market Cap

7.7M

Price/Earnings (Trailing)

-0.14

Price/Sales (Trailing)

1.95

EV/EBITDA

0.07

Price/Free Cashflow

-0.22

JAGX Price/Sales (Trailing)

JAGX Profitability

Return on Equity

-1.5K%

Return on Assets

-106.23%

Free Cashflow Yield

-462.43%

JAGX Fundamentals

JAGX Revenue

JAGX Earnings

Earnings (TTM)

-54.5M

Earnings Y/Y

-3.42%

Earnings Q/Q

-34.28%

Price Action

52 Week Range

0.086.15

(Low)(High)

Last 7 days

5280.4%

Last 30 days

5274.6%

Last 90 days

3335.1%

Trailing 12 Months

532.5%

JAGX Financial Health

Current Ratio

0.94

JAGX Investor Care

Shares Dilution (1Y)

132.03%

Diluted EPS (TTM)

-71.25

Peers (Alternatives to Jaguar Health)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	442.3B	96.0B	-5.17%	5.99%	23.09	4.61	5.02%	7.14%
LLY	308.2B	29.2B	-5.85%	46.05%	51.09	10.54	5.34%	1.02%
MRK	278.4B	59.0B	-2.99%	42.09%	18.24	4.72	27.84%	112.03%
PFE	252.2B	99.9B	-13.74%	-10.43%	8.47	2.53	45.01%	53.21%
BMY	155.8B	46.7B	-0.75%	18.09%	23.33	3.33	2.79%	223.53%
MID-CAP
PRGO	5.0B	4.4B	10.99%	-2.60%	-46.61	1.14	1.80%	57.67%
SUPN	2.2B	659.0M	10.52%	42.11%	58.22	3.33	16.78%	-53.92%
SMALL-CAP
TLRY	1.9B	613.6M	11.47%	-46.75%	-3.76	3.11	37.73%	-7.19%
RETA	1.5B	3.1M	16.69%	58.71%	-4.91	486.39	-77.09%	-12.24%
CGC	1.3B	-	18.45%	-62.70%	-0.44	1.95	-4.11%	-144.36%
ACRS	1.1B	23.5M	8.75%	61.26%	-13.48	47.07	243.57%	-1.04%
CRON	953.4M	112.7M	-3.54%	-28.57%	-4.26	8.46	45.53%	40.26%
INVA	902.9M	-	-6.12%	-22.22%	2.7	2.34	10.49%	-16.07%
OCUL	300.3M	49.7M	46.44%	-30.92%	-5.06	6.04	28.95%	32.80%
ENDP	94.1M	2.6B	-43.99%	-88.43%	-0.03	0.04	-13.88%	-4855.92%

Financials for Jaguar Health

Income Statement (Last 12 Months)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	12.9%	9,385,000	8,316,000	6,516,000	5,055,000	5,775,000
EBITDA Margin	6.8%	-3.12	-3.35	-	-	-
EBT Margin	3.4%	-3.60	-3.73	-	-	-
Net Income Margin	3.4%	-3.60	-3.73	-	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	2.8%	51	50	53	53	59
Current Assets	7.9%	25	23	28	28	24
Cash Equivalents	17.2%	11	9	17	17	12
Inventory	-2.1%	7	7	5	5	5
Net PPE	-1.9%	1	1	1	1	1
Liabilities	1.2%	48	47	45	41	38
Current Liabilities	17.7%	27	23	19	15	12
Shareholder's Equity	30.5%	4	3	8	12	22
Retained Earnings	-5.1%	-259.40	-246.80	-237.48	-219.49	-205.20
Additional Paid-In Capital	5.4%	263	250	246	231	227
Accumulated Depreciation	3.4%	0	0	0	0	0
Shares Outstanding	33.5%	1	1	1	1	-
Minority Interest	-217.1%	-0.05	0	0	0	-

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	2.5%	-35,604.00	-36,507.00	-35,957.00	-34,970.00	-30,108.00
Share Based Compensation	-9.7%	3,963	4,387	4,403	3,974	3,472
Cashflow From Investing	Infinity%	20,844	0	-6.00	-20,956.00	-
Cashflow From Financing	65.6%	24,664	14,890	21,219	43,937	51,618

* denotes actual numbers (not divided by Thousands)

Risks for JAGX

What is the probability of a big loss on JAGX?

100%

Probability that Jaguar Health stock will be more than 20% underwater in next one year

100%

Probability that Jaguar Health stock will be more than 30% underwater in next one year.

100%

Probability that Jaguar Health stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JAGX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Jaguar Health was unfortunately bought at previous high price.

Drawdowns

Returns for JAGX

Cumulative Returns on JAGX

-65.9%

7-Year Cumulative Returns

-59.0%

5-Year Cumulative Returns

29.1%

3-Year Cumulative Returns

What are the long-term rolling returns for JAGX?

FIve years rolling returns for Jaguar Health.

Annualized Returns

Which funds bought or sold JAGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-23	Moisand Fitzgerald Tamayo, LLC	new	-	9	9	-%
2023-01-13	Merit Financial Group, LLC	unchanged	-	-2,480	2,520	-%
2022-11-15	JANE STREET GROUP, LLC	new	-	3,000	3,000	-%
2022-11-15	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
2022-11-15	STATE STREET CORP	unchanged	-	-19,000	22,000	-%
2022-11-14	Stonebridge Capital Advisors LLC	unchanged	-	-	-	-%
2022-11-14	ADVISOR GROUP HOLDINGS, INC.	reduced	-82.25	-	-	-%
2022-11-14	Atria Wealth Solutions, Inc.	unchanged	-	-	3,000	-%
2022-11-14	COMMONWEALTH EQUITY SERVICES, LLC	new	-	3,000	3,000	-%
2022-11-14	WELLS FARGO & COMPANY/MN	reduced	-0.43	-	-	-%

Latest Funds Activity

Are funds buying JAGX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own JAGX

No. of Funds

Jaguar Health News

Schedule 13G FIlings of Jaguar Health

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Aug 26, 2022	streeterville capital llc	9.75%	11,500,000	SC 13G
May 10, 2022	mailman joshua	11.1%	8,614,138	SC 13G
Jan 11, 2022	oasis capital, llc	9.99%	4,604,484	SC 13G
Feb 12, 2021	sagard capital partners, l.p.	2.8%	1,910,043	SC 13G/A
Feb 11, 2021	ionic ventures, llc	0%	0	SC 13G/A
Jan 25, 2021	oasis capital, llc	9.99%	6,874,665	SC 13G
Nov 04, 2020	iliad research & trading, l.p.	7.88%	4,750,000	SC 13G
Sep 25, 2020	chicago venture partners, l.p.	8.28%	3,333,333	SC 13G
Sep 11, 2020	sagard capital partners, l.p.	6.1%	2,476,974	SC 13G
Jul 07, 2020	oasis capital, llc	9.99%	1,849,468	SC 13G

JAGX Fair Value

Recent SEC filings of Jaguar Health

View All Filings

Date Filed	Form Type	Document
Jan 23, 2023	8-K	Current Report
Jan 06, 2023	8-K	Current Report
Jan 03, 2023	4	Insider Trading
Dec 30, 2022	8-K	Current Report
Dec 28, 2022	4	Insider Trading
Dec 28, 2022	4	Insider Trading
Dec 28, 2022	4	Insider Trading
Dec 28, 2022	4	Insider Trading
Dec 28, 2022	4	Insider Trading
Dec 16, 2022	DEFR14A	DEFR14A

Latest Insider Trading transactions for JAGX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-12-31	Wolin Jonathan S.	bought	9.51	0.03	317	chief of staff, cco & gc
2022-05-18	Siegel Jonathan B.	acquired	-	-	12,133	-
2022-05-18	MICEK JOHN	acquired	-	-	12,133	-
2022-05-18	Divis Gregory J	acquired	-	-	12,133	-
2022-05-18	BOCHNOWSKI JAMES J	acquired	-	-	13,133	-
2022-04-05	Lizak Carol R.	acquired	-	-	4,513	chief financial officer
2022-04-05	Wolin Jonathan S.	acquired	-	-	6,666	chief of staff, cco & gc
2022-04-05	Chaturvedi Pravin R	acquired	-	-	3,333	chief scientific officer
2022-04-05	CONTE LISA A	acquired	-	-	45,000	ceo and president
2022-04-05	King Steven R.	acquired	-	-	13,333	chief of sustainable supply

About Jaguar Health

Lisa A. Conte

www.jaguaranimalhealth.com

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

JAGX Income Statement

2022-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Cost of product revenue	$ 613,000	$ 617,000	$ 1,524,000	$ 1,864,000
Research and development	5,940,000	3,312,000	13,336,000	9,597,000
Sales and marketing	2,109,000	2,261,000	7,089,000	6,596,000
General and administrative	4,384,000	3,969,000	14,876,000	12,450,000
Series 3 warrants inducement expense				1,462,000
ELOC warrants inducement expense				172,000
Total operating expenses	13,046,000	10,159,000	36,825,000	32,141,000
Loss from operations	(9,896,000)	(9,529,000)	(28,129,000)	(29,886,000)
Interest expense	(2,731,000)	(2,078,000)	(10,089,000)	(5,988,000)
Loss on extinguishment of debt			(2,187,000)	(753,000)
Change in fair value of financial instruments and hybrid instrument designated at Fair Value Option	176,000	(565,000)	652,000	(1,639,000)
Other expense, net	(158,000)	(20,000)	(410,000)	(16,000)
Loss before income tax	(12,609,000)	(12,192,000)	(40,163,000)	(38,282,000)
Income tax expense
Net loss and comprehensive loss	(12,609,000)	(12,192,000)	(40,163,000)	(38,282,000)
Net loss attributable to noncontrolling interest	(89,000)		(290,000)
Net loss attributable to common shareholders	(12,520,000)	(12,192,000)	(39,873,000)	(38,282,000)
Net loss attributable to common shareholders (diluted)	$ (12,520,000)	$ (12,192,000)	$ (39,873,000)	$ (38,282,000)
Net loss per share, basic	$ (0.12)	$ (0.27)	$ (0.49)	$ (0.87)
Net loss per share, diluted	$ (0.12)	$ (0.27)	$ (0.49)	$ (0.87)
Weighted-average common shares outstanding, basic	106,362,178	45,840,262	81,657,061	44,167,885
Weighted-average common shares outstanding, diluted	106,362,178	45,840,262	81,657,061	44,167,885
Product revenue
Revenue
Total revenue	$ 3,150,000	$ 630,000	$ 8,696,000	$ 2,255,000

JAGX Balance Sheet

2022-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 10,561,000	$ 17,051,000
Accounts receivable	1,825,000	1,709,000
Other receivable	634,000	435,000
Inventory	6,601,000	4,900,000
Prepaid expenses and other current assets	5,587,000	4,339,000
Total current assets	25,208,000	28,434,000
Property and equipment, net	572,000	650,000
Operating lease - right-of-use asset	1,104,000	1,084,000
Intangible assets, net	22,561,000	22,651,000
Other assets	1,842,000	446,000
Total assets	51,287,000	53,265,000
Current liabilities:
Accounts payable	6,285,000	4,929,000
Accrued liabilities	8,504,000	7,117,000
Warrant liability		1,000
Operating lease liability, current	418,000	240,000
Notes payable, current	11,737,000	3,184,000
Total current liabilities	26,944,000	15,471,000
Operating lease liability, net of current portion	738,000	919,000
Notes payable, net of discount, net of current portion (includes hybrid instrument designated at Fair Value Option amounting to $7.2 million and $7.8 million as of September 30, 2022 and December 31, 2021, respectively)	20,006,000	25,022,000
Total liabilities	47,688,000	41,412,000
Commitments and contingencies (See Note 7)
Stockholders' equity
Additional paid-in capital	263,001,000	231,100,000
Noncontrolling interest	(48,000)	242,000
Accumulated deficit	(259,367,000)	(219,494,000)
Total stockholders' equity	3,599,000	11,853,000
Total liabilities and stockholders' equity	51,287,000	53,265,000
Series D perpetual preferred stock
Current liabilities:
Series D perpetual preferred stock: $0.0001 par value; 977,300 shares authorized at September 30, 2022 and December 31, 2021; zero shares issued and outstanding at September 30, 2022 and December 31, 2021
Series B-2 Preferred Stock
Stockholders' equity
Preferred stock value
Series C perpetual preferred stock
Stockholders' equity
Preferred stock value
Common stock - voting
Stockholders' equity
Common stock value	13,000	5,000
Common stock - non-voting
Stockholders' equity
Common stock value